Zurich’s SkyCell raises €53.5M from M&G’s Catalyst to revolutionise pharmaceutical logistics
Zurich-based SkyCell, a technology company that aims to revolutionise global pharmaceutical logistics, announced that it has secured $57M (approximately €53.51M) in a fresh round of funding. The investment came from Catalyst, a part of M&G Investments’ $6B purpose-led private assets strategy.
SkyCell addresses the global challenge of safe medicine access with its Hybrid container concept. Its door-to-door solutions protect pharmaceuticals from extreme temperatures (-30°C to +70°C) and reduce the industry’s product loss due to temperature excursions.